ライフサイエンスコーパス: antineoplastic agent

1 ted apoptosis by etoposide, a representative antineoplastic agent.

2 to improve the therapeutic efficacy of this antineoplastic agent.

3 oing Phase I clinical testing as a potential antineoplastic agent.

4 ed to sensitize these cancer cells toward an antineoplastic agent.

5 as significant data supporting its use as an antineoplastic agent.

6 e II diabetes that has gained interest as an antineoplastic agent.

7 )F-FLT) in assessing its effectiveness as an antineoplastic agent.

8 rent clinical assessment of clioquinol as an antineoplastic agent.

9 n attractive candidate for development as an antineoplastic agent.

10 hibitor developed specifically for use as an antineoplastic agent.

11 door for clinical trials evaluating it as an antineoplastic agent.

12 linical information on gallium nitrate as an antineoplastic agent.

13 the tumor-specific activity of DNA-damaging antineoplastic agents.

14 of IAP proteins can modulate the efficacy of antineoplastic agents.

15 ificantly increases the efficacy of existing antineoplastic agents.

16 ts that can be mitigated by encapsulation of antineoplastic agents.

17 plausible pharmacological strategy for novel antineoplastic agents.

18 e viable resources in the development of new antineoplastic agents.

19 ases as novel targets for the development of antineoplastic agents.

20 iatric patients who receive high-emetic-risk antineoplastic agents.

21 ramifications for the use of these drugs as antineoplastic agents.

22 ications of these findings for resistance to antineoplastic agents.

23 nts may have applicability as biotherapeutic antineoplastic agents.

24 signal transduction modulators as potential antineoplastic agents.

25 tients who are treated with high emetic risk antineoplastic agents.

26 the development of new immunosuppressive and antineoplastic agents.

27 proach for the development of new classes of antineoplastic agents.

28 e for the development of cdk2 antagonists as antineoplastic agents.

29 n cancer patients who receive these drugs as antineoplastic agents.

30 ellular targets of many structurally diverse antineoplastic agents.

31 ramide in the lethal actions of conventional antineoplastic agents.

32 on may contribute to NF-kappaB activation by antineoplastic agents.

33 l sensitivity to this promising new class of antineoplastic agents.

34 form the basis for the development of novel antineoplastic agents.

35 timal combinations of these drugs with other antineoplastic agents.

36 as mapped with respect to several classes of antineoplastic agents.

37 nique intracellular and selective target for antineoplastic agents.

38 asing their susceptibility to cycle-specific antineoplastic agents.

39 er or cancer survivors treated with systemic antineoplastic agents.

40 olecules targeting translation initiation as antineoplastic agents.

41 outinely, alone or in combination with other antineoplastic agents.

42 rotoxicity profiles of an important class of antineoplastic agents.

43 multiple oncoproteins may lead to effective antineoplastic agents.

44 ifaceted approach for the development of new antineoplastic agents.

45 to improve performance and safety of current antineoplastic agents.

46 ng beta-lactam antibiotics and antiviral and antineoplastic agents.

47 for designing biocompatible target specific antineoplastic agents.

48 described possible activity of quinolones as antineoplastic agents.

49 lation to cytotoxic chemotherapy or targeted antineoplastic agents.

50 resistance to paclitaxel and possibly other antineoplastic agents.

51 entify complex III as a potential target for antineoplastic agents.

52 e proposal that these ligands may be used as antineoplastic agents.

53 reast cancer cells to cytoskeletal targeting antineoplastic agents.

54 logic utility as angiogenesis inhibitors and antineoplastic agents.

55 by current or previous treatment with other antineoplastic agents.

56 hione conjugates and several natural product antineoplastic agents.

57 ed for cancer cell apoptosis induced by many antineoplastic agents.

58 metabolism and may be a suitable target for antineoplastic agents.

59 a group, are unresponsive to treatment with antineoplastic agents.

60 l scaffold to improve the design of specific antineoplastic agents.

61 logic-based therapies are being developed as antineoplastic agents.

62 In this study, we examined whether antineoplastic agents 5-fluorouracil (5-FU) and dacarbaz

63 b, alone or in combination with the standard antineoplastic agents, 5-fluoruracil or irinotecan.

64 n of cellular apoptotic responses to various antineoplastic agents, a laser-based technology, Optopho

65 tide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the his

66 bacterial, fungal, and parasitic infections, antineoplastic agents against cancer cells, and perturba

67 ts with a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical cl

68 tioning a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical cl

69 n continue to be treated with this important antineoplastic agent and how such retreatment might be u

70 e transport of many amphiphilic antibiotics, antineoplastic agents and cytotoxic compounds that are d

71 city that are reported to be associated with antineoplastic agents and discuss their putative mechani

72 ic investigation of PPARdelta antagonists as antineoplastic agents and implicate altered PPARdelta-cy

73 t from mechanisms used by some DNA-damaging, antineoplastic agents and other apoptotic stimuli.

74 5'Bcl-x AS sensitized cells to several antineoplastic agents and radiation and was effective in

75 , for a 1-year period, suffered reactions to antineoplastic agents and were referred to the Desensiti

76 kers has revealed many potential targets for antineoplastic agents, and a particularly important aber

77 argeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges a

78 ncer cell proliferation by aurones and known antineoplastic agents, and in vitro inhibition of tubuli

79 in C given before mechanistically dissimilar antineoplastic agents antagonizes therapeutic efficacy i

80 new low molecular weight, protein-targeted, antineoplastic agents approved by the US FDA 2019-2023.

81 tional chemotherapy, many molecular targeted antineoplastic agents are available in oral formulation,

82 Taxane antineoplastic agents are extensively taken up into hepa

83 Although oral antineoplastic agents are generally well-tolerated, card

84 Importantly, most clinically useful antineoplastic agents are less potent and efficacious in

85 or in combination with gemcitabine and other antineoplastic agents are warranted.

86 -870,893 alone and in combination with other antineoplastic agents are warranted.

87 o asparaginyl residues and that DNA-damaging antineoplastic agents as well as other stimuli can incre

88 The antineoplastic agent benzyl isothiocyanate (BITC) acts b

89 f advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163)

90 otic enzyme that inactivates the widely used antineoplastic agent bleomycin (BLM) and is a primary ca

91 The antineoplastic agent bryostatin-1 (bryo-1) possesses pow

92 was combined with seven of the eight tested antineoplastic agents but was highly dependent upon admi

93 Doxorubicin is a highly effective antineoplastic agent, but it can produce the serious sid

94 pathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the

95 ate the response of an individual's tumor to antineoplastic agents, but these tumor fragments are cul

96 ion can affect the sensitivity of cancers to antineoplastic agents by altering expression of genes cr

97 ADCs is to improve the therapeutic index of antineoplastic agents by restricting their systemic deli

98 This antineoplastic agent can be delivered effectively by bot

99 These highly active antineoplastic agents can be used for incorporation into

100 e induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficac

101 ce or its displacement from the chromatin by antineoplastic agents caused an increase in the levels o

102 sis included young age and chemotherapy with antineoplastic agents, cefotaxime, vancomycin, and cefta

103 clude the aminoglycoside antibiotics and the antineoplastic agent cisplatin.

104 The present SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focuse

105 Hydroxyurea is an antineoplastic agent commonly used to treat myeloprolife

106 sed in the present study for delivery of the antineoplastic agent daunomycin to the rat brain.

107 Imatinib, an antineoplastic agent, demonstrated antiinflammatory and

108 , CREB, SP-1, or TFIID were not activated by antineoplastic agents demonstrating specificity of NF-ka

109 ast, docetaxel (Taxotere), a closely related antineoplastic agent, did not activate SXR and displayed

110 novel procedure to couple enzymatically the antineoplastic agent doxorubicin (Dox) on the galactose

111 rs and is suppressed in cardiac cells by the antineoplastic agent doxorubicin.

112 n vitro and in vivo tumor sensitivity to the antineoplastic agent doxorubicin.

113 growth factors, and pharmacotherapy with an antineoplastic agent (Erlotinib).

114 xel (Taxol) is a potent and highly effective antineoplastic agent for the treatment of advanced, drug

115 our data, bortezomib represents a promising antineoplastic agent for the treatment of ATC.

116 port the clinical development of CV890 as an antineoplastic agent for the treatment of localized or m

117 cacy and diminish toxic effects derived from antineoplastic agents for patient benefit.

118 Currently, FTIs are being explored as antineoplastic agents for the treatment of several malig

119 structurally diverse hydrophobic amphipathic antineoplastic agents from cells, with different mechani

120 The use of interleukin 2 (IL-2) as an antineoplastic agent has been limited by the serious tox

121 Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occur

122 activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were trea

123 , a PP2A inhibitor which has been used as an antineoplastic agent in clinical trials, is also able to

124 th RXR-selective ligand may thus be a useful antineoplastic agent in differentiation induction therap

125 275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by

126 IFN-alpha is an antineoplastic agent in the treatment of several solid a

127 e inhibitor to undergo clinical trials as an antineoplastic agent in the United States, has attracted

128 orubicin (DOXO) is one of the most effective antineoplastic agents in clinical practice.

129 notherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy f

130 from combining flavopiridol with eight other antineoplastic agents in four different administration s

131 d consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are recei

132 timal dose for use in combination with other antineoplastic agents in pediatric patients.

133 ggest that As(2)O(3) and AA may be effective antineoplastic agents in refractory MM and that AA might

134 Approximately 44% of patients received antineoplastic agents in the last 30 days of life throug

135 d in B cell lymphomas by anti-Fas or various antineoplastic agents in the presence and absence of FDC

136 ng term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7

137 d resistant (MCF-7/Adr-, T47D, and SKBr3) to antineoplastic agents, incubation with the sigma-2 subty

138 The demonstration that many antineoplastic agents induce apoptosis in susceptible ce

139 paullones, a dual property observed in other antineoplastic agents influencing phosphoester transfer.

140 Desensitization to antineoplastic agents is becoming a standard of care.

141 The therapeutic value of DNA-damaging antineoplastic agents is dependent upon their ability to

142 -The clinical efficacy of anthracycline antineoplastic agents is limited by a high incidence of

143 The clinical utility of antineoplastic agents is limited by the development of d

144 inical use of doxorubicin, widely used as an antineoplastic agent, is markedly hampered by severe car

145 ed the sensitivity of these cells to several antineoplastic agents known to be cell cycle-dependent o

146 though some of the mechanisms by which these antineoplastic agents lead to hypertension have been cha

147 tial for increased exposure of the tumour to antineoplastic agents leading to improved cytotoxicity.

148 Antineoplastic agents loaded on 50-100-microm microspher

149 the side effects of cisplatin, a widely used antineoplastic agent, major efforts have been made to de

150 storically, it has been well recognized that antineoplastic agents may have adverse effects on multip

151 idoreductase 1 (NQO1) on the activity of the antineoplastic agent mitomycin C (MC) under aerobic and

152 List price increases were lowest (59%) for antineoplastic agents (n = 44), but discounts only offse

153 as osteosarcoma, for preclinical testing of antineoplastic agents offers significant advantages over

154 xic effect of ET-743 combined with six other antineoplastic agents on human breast cancer cell lines,

155 ated the effect of bryostatin-1 (Bryo-1), an antineoplastic agent, on dendritic cell (DC) maturation,

156 antiemetic regimens that are appropriate for antineoplastic agents or radiotherapy being administered

157 mens for adults who receive high-emetic-risk antineoplastic agents or who experience breakthrough nau

158 apeutic tool for hypersensitivity to several antineoplastic agents (oxaliplatin, carboplatin, paclita

159 The antineoplastic agent paclitaxel (TaxolTM), a microtubule

160 consist of topo I-targeting agents and other antineoplastic agents, particularly DNA-damaging agents.

161 The performance and safety of current antineoplastic agents, particularly water-insoluble drug

162 ne compound previously used clinically as an antineoplastic agent potentiates the presynaptic functio

163 edules and combining temozolomide with other antineoplastic agents, radiation therapy, or drug resist

164 Antibody-drug conjugates (ADC) are antineoplastic agents recently introduced into the antit

165 omplex subunits confer resistance to several antineoplastic agents routinely used for the treatment o

166 Targeted antineoplastic agents show great promise in the treatmen

167 menting the transvascular delivery of larger antineoplastic agents such as gene targeting vectors and

168 F ablation augments the delivery of systemic antineoplastic agents such as liposomal doxorubicin.

169 The common use of antineoplastic agents such as mitomycin C, doxorubicin,

170 We also found that ET-743, a potent antineoplastic agent, suppressed MDR1 transcription by a

171 Pharmacological traits of the antineoplastic agent taxol may originate in part from it

172 All antineoplastic agents tested caused mitochondrial membra

173 nd colony formation after treatment with all antineoplastic agents tested.

174 Doxorubicin (Dox) is a widely used antineoplastic agent that can cause heart failure.

175 o Targeted HSV-1 editing results in a unique antineoplastic agent that enables inflammation without m

176 TAS-103 is a novel antineoplastic agent that is active against in vivo tumo

177 Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not

178 Bryostatin-1, a macrocyclic lactone, is an antineoplastic agent that potently activates protein kin

179 Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is m

180 tment with paclitaxel (trade name Taxol), an antineoplastic agent that stabilizes cellular microtubul

181 Paclitaxel, an antineoplastic agent that stabilizes microtubules and ar

182 raf-1 kinase may be of considerable value as antineoplastic agents that display activity against a wi

183 In contrast to most other antineoplastic agents that generate reactive oxygen spec

184 Vinca alkaloids are antineoplastic agents that halt cell division at metapha

185 Therapy with antineoplastic agents that inhibit EGFR and MEK is frequ

186 thesis that flavopiridol, like several other antineoplastic agents that kill noncycling cells, might

187 at can enhance the efficacy of biguanides as antineoplastic agents that target cancer cell energy met

188 rease in apoptosis in cells treated with the antineoplastic agents that was not due to up-regulation

189 n deazapurines as antibiotic, antiviral, and antineoplastic agents, the biosynthetic route toward dea

190 of development and availability of new oral antineoplastic agents, the purpose of this review is to

191 ew the development of successful preclinical antineoplastic agents, their associated limitations, and

192 ficant advancements in nanotechnology-driven antineoplastic agents, there remains a conspicuous gap i

193 zymatically mediated, glycosidic coupling of antineoplastic agents to antibodies specific for tumor-a

194 might be useful in targeting the delivery of antineoplastic agents to such cancers.

195 om our own laboratory, exploring how various antineoplastic agents trigger different forms of autopha

196 Paclitaxel (Taxol) is a frontline antineoplastic agent used to treat a variety of solid tu

197 of the interaction between ET-743 and other antineoplastic agents using the combination index method

198 pressing) and MCJ-transfected OV167 cells to antineoplastic agents was evaluated.

199 a desensitization to cell cycle-independent antineoplastic agents was found in the cells arrested by

200 increased resistance to cell cycle-dependent antineoplastic agents was found in the cells when the ex

201 apy, 51 candidate genes from the pathways of antineoplastic agents were resequenced to identify commo

202 concentrations, enhanced the effects of both antineoplastic agents when used in combination.

203 Adriamycin is a popular antineoplastic agent whose ability to form covalent addu

204 is likely that interest in CDK inhibitors as antineoplastic agents will continue for the foreseeable

205 Deoxynyboquinone (DNQ) is a potent antineoplastic agent with an unknown mechanism of action